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Objective: To assess the bioequivalence of single dose trazodone hydrochloride USP
100mg tablets administered as an oral dose under fed condition.
Methods: This study was an open-label, balanced, randomized, two-sequence,
two-treatment, two-period, single oral dose, crossover bioequivalence study in healthy,
adult, human subjects under fed conditions. After an overnight fast of at least 10 h,
the subjects were served a high fat and high calorie vegetarian breakfast, which
they were required to consume within 30min. A single oral dose (100 mg) of either
the test or the reference product was administered to the subjects. The primary
pharmacokinetic parameters, maximum plasma concentration (Cmax) and area under the
plasma concentration–time curve (AUC) from time zero to last measurable concentration
(AUC0−t) and extrapolated to infinity (AUC0−∞) were compared by an analysis of variance
using log-transformed data. Bioequivalence was concluded if the 90% confidence
intervals (CIs) of the adjusted geometric mean (gMean) ratios for Cmax and AUC were
within the predetermined range of 80–125%, in accordance with regulatory requirements.
Results: For the test formulation, the trazodone gMean Cmax was 1480.9 ng/mL (vs.
1520.2 ng/mL for reference), AUC0−t was 18193.0 ng·h/mL (vs. 18209.8 ng·h/mL) and
AUC0−∞ was 19346.3 ng·h/mL (vs. 19393.4 ng·h/mL). The 90% CIs for the ratio
(test/reference) were 93.0–102.0% for Cmax, 96.7–103.2% for AUC0−t and 96.1–103.5%
for AUC0−∞. There were no deaths or serious adverse events during the conduct of the
study.
Conclusion: Test product when compared with the Reference product meets the
bioequivalence criteria with respect to the extent of absorption of trazodone under fed
condition.
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Introduction
Trazodone Hydrochloride is an antidepressant chemically
unrelated to tri-cyclic, tetra-cyclic, or other known
antidepressant agents. The mechanism of trazodone
hydrochloride’s antidepressant action in man is not fully
understood. In animals, trazodone selectively inhibits its
serotonin uptake by brain synaptosomes and potentiates
the behavioral changes induced by the serotonin precursor,
5-hydroxytryptophan. Trazodone is not a monoamine oxidase
inhibitor and, unlike amphetamine-type drugs, does not
stimulate the central nervous system. Trazodone is rapidly and
almost completely absorbed from the GI tract following oral
administration. The rate and extent of absorption are affected by
the presence of food. Peak plasma concentrations of trazodone
occur approximately 1 h after oral administration when the drug
is taken on an empty stomach or 2 h after oral administration
when taken with food.
When trazodone is taken shortly after the ingestion of food,
there may be a slight increase (up to 20%) in the amount of drug
absorbed. Distribution of trazodone into human body tissues
and fluids has not been determined. Plasma concentrations
of trazodone decline in a biphasic manner. Following oral
administration of single doses of 25, 50, or 100mg of trazodone
to healthy, fasted adults in another study, mean peak plasma
trazodone concentrations were 490, 860, and 1620 ng/mL,
respectively (Nilsen and Dale, 1992). The half-life of trazodone
in the initial phase is about 3–6 h and the half-life in the terminal
phase is about 5–9 h. The clearance of trazodone from the body
shows wide inter-individual variations. The therapeutic range for
plasma trazodone concentrations and the relationship of plasma
concentrations to clinical response and toxicity have not been
established.
As per another reported(Gammans et al., 1984) study,
following single doses, trazodone is rapidly and completely
absorbed(Jauch et al., 1976; Ankier et al., 1981; Cassia et al., 1982)
with peak plasma concentrations achieved 0.5–2 h following
administration. The mean elimination half-life of trazodone
has been variously reported as 4 h (Ankier et al., 1981) and
12 h (Jauch et al., 1976). Trazodone is eliminated primarily by
metabolism(Biocchi et al., 1974).
The aim of the study was to compare the bioavailability
and assess the pharmacokinetic profile of the test formulation
Trazodone Hydrochloride tablets USP 100mg manufactured
by Intas Pharmaceuticals Ltd., India in comparison with the
reference formulation TrazoDONE Hydrochloride tablets USP
100mg manufactured by Apotex Inc., Toronto, Canada.
Subjects and Methods
This was a single-center (Lambda Therapeutic Research Ltd,
Ahmedabad, India), randomized, single-dose, open-label, 2-
treatment, 2-period, 2-sequence, crossover trial conducted in
healthy volunteers between October and November 2013. The
Independent Ethics Committee reviewed the study Protocol,
Informed consent Form, Curriculum Vitae of Investigators
and Product information (American Society of Health-System
Pharmacists Inc, 2009). The study was conducted in accordance
with local regulations and the Declaration of Helsinki and Good
Clinical Practice (Guideline for Good Clinical Practice, 1996;
Declaration of Helsinki, 2008). Written informed consent was
obtained from all subjects before performing any trial-related
activities. For this bioequivalence study, a crossover design was
planned as per the USFDA requirements (US Department of
Health and Human Services, Center for Drug and Research,
2003). A crossover study was conducted on 56 subjects under fed
conditions.
Subjects
All subjects willing to participate in the study were screened prior
to their enrolment, in order to assess their eligibility by satisfying
all of the inclusion and exclusion criteria. During screening, the
medical history of the subjects was elicited and they underwent
a general clinical examination, measurement of blood pressure,
heart rate, oral body temperature, respiratory rate, 12-lead
Electrocardiogram (ECG), clinical laboratory evaluations, chest
X-ray and immunological tests for Human Immunodeficiency
Virus (HIV), Hepatitis B Surface antigen (HBsAg), Hepatitis C
Virus (HCV). This procedure was conducted within 21 days
prior to the first dose of investigational medicinal product (IMP)
administration. Healthy human subjects aged 18–45 years with a
body mass index (BMI) of 18.5–27.5 calculated as kg/(height in
m)2 were considered for the study. Additional exclusion criteria
included any history or presence of asthma or nasal polyp or
any other non-steroidal anti-inflammatory drugs (NSAID)—
induced urticaria, smokers, who smoked >10 cigarettes per
day or donation of blood (350ml), or receipt of an IMP or
participation in a drug research study within 90 days prior to
receiving the first dose of study medicine. No female volunteers
were enrolled in the study.
Study Design and Treatments
In this study the screening phase was carried out within 21 days
prior to the scheduled dosing day of Period-I. The duration of the
clinical part of the study was about 8 days (11 h prior to the dose
administration in Period-I until the last pharmacokinetic sample
in Period-II). Based on available and data and statistical analysis
and elimination half-life of trazodone, a wash out period of 4
days was kept in between the dosing days of the study periods.
In this study with a crossover design, each subject received
both the treatments (test drug and reference drug) during the
study. Hence, every subject acted as his own control and no
separate group of subjects was required to act as the control
group. The sequence of administration was determined by the
randomization schedule.
After an overnight fast of at least 10 h, the subjects were served
a high fat (∼50% of total caloric content of the meal) and high
calorie (∼800–1000 calories) vegetarian breakfast consist of 65 g
of Carbohydrates (260Kcal), 60 g of Fats (540Kcal), and 34 g
of Proteins (137Kcal) resulting into total calories (Kcal) of 937,
which they required to consume within 30min. A single oral
dose (100mg) of either the test or the reference product was
administered to the subjects at 30min after serving the breakfast.
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The IMP was administered in sitting posture with 240mL of
drinking water at ambient temperature.
This activity was followed by a mouth check to assess the
compliance to dosing. All the subjects were instructed to remain
in sitting posture or ambulatory position for the first 3 h after
administration of IMP in each period. During each period
subjects remained in the study center until blood samples had
been taken 48 h after dosing.
Pharmacokinetic Evaluation
Blood samples were collected through an indwelling intravenous
cannula (Venflon) placed in a forearm vein of the subjects. A
total of 23 blood samples, each of 05mL were collected from each
subject in each period at pre-dose (0.0 h) and at 20min, 40min
and at 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 2.75, 3, 3.5, 4, 5, 6, 8, 10, 12, 16,
24, 36, and 48 h following drug administration. Immediately after
collection of blood, the collection tube (vacutainer) was inverted
gently several times to ensure the mixing of tube contents [i.e.,
anticoagulant Dipotassium Ethylene Diamine Tetraacetic Acid
(K2EDTA)]. The blood samples were centrifuged at 3000 ref for
5min below 10◦C to separate plasma. The separated plasma was
stored in a freezer below−55◦C.
The plasma samples of subjects were analyzed using a
validated LC-MS/MS method (Kale et al., 2014) for trazodone
at the Bioanalytical facility of Lambda Therapeutic Research
Ltd., Ahmedabad, India. The method was validated as per the
regulatory guideline (US Department of Health and Human
Services, Food and Drug Administration, 2001). Calibration
curves using an eight-point calibration curve standards for
trazodone, with concentration ranging from 5.2 ng/mL to
3025.2 ng/mL, were used to determine the concentration of
Trazodone in the samples of various subjects.
Plasma concentrations of trazodone were analyzed using
liquid chromatography mass spectrometry procedures, which
were fully validated and developed at Lambda Therapeutic
Research Ltd, Ahmedabad, India. Briefly, trazodone plasma
concentrations were measured following protein precipitation
extraction (internal standard trazodone-d6) by liquid
chromatography mass spectrometry (LC-MS/MS) using a
Eclipse XBD C8 150 X 4.6mm, 5µm column, (mobile phase 70%
methanol and 30% 2mM Ammonium Format buffer pH 3.0).
The limit of quantification was 5.2 ng/mL. Assay performance
was assessed by back-calculation of calibration standards,
tabulation of the standard curve fit function parameters and
measurement of quality control (QC) samples. In all the cases,
analytical run was rejected or accepted on the basis of the results
obtained for QC samples run with that particular analytical
run. There were four levels of QCs spread across the calibration
curve range analyzed with each run in duplicates. The inter-day
precision and accuracy of QCs during the study were from
2.0–7.7 to 100.2–102.9%, respectively, which were within the
acceptance range of ±15% from the nominal value. Validation
data documented adequate accuracy, precision and specificity of
the liquid chromatography mass spectrometry assays employed
for the study.
A total of 2169 samples were analyzed during the study. Out of
these, 231 samples were reanalyzed to establish incurred sample
reproducibility (ISR). Out of the incurred samples selected
per subject, at least one sample was close to the maximum
concentration and another sample was near the elimination
phase to cover the entire concentration range. A total of 223
(96.5%) samples were within the acceptance criteria of ±20%
differences between two values.
Safety Evaluation
All the subjects underwent a pre-enrolment laboratory
parameters evaluation including tests for hematology,
biochemistry, immunology, and urine analysis. The post-
study safety assessments included hematology and biochemistry
(except random glucose, sodium, potassium, and chloride).
Sitting blood pressure and radial pulse were measured during
each clinical examination, prior to administration of study drug
and at approximately 02 and 11 h after administration of IMP in
each period. Subjects were questioned for well-being at the time
of clinical examinations and at the time of recording of vital signs
in each period. Adverse events were collected during each study
period with severity (mild, moderate, or severe) and investigator
assessment of the relationship to the study medication (definite,
possible, doubtful, or none).
Pharmacokinetic Analyses
The pharmacokinetic parameters were derived individually for
each analyzed subject from the concentration vs. time profiles
of trazodone in plasma. The primary variables were the area
under the plasma concentration-time curve from time 0 to
the last quantifiable data point (AUC0−t), from time zero
extrapolated to infinity (AUC0−∞) and Cmax. Time of maximum
exposure (tmax) was a secondary variable. Non-compartmental
analysis of plasma concentration-time data was performed
usingWinNonlin R© Professional software (Version 5.3, Pharsight
Corporation, USA). Actual time points of the sample collection
were used for the calculation of pharmacokinetic parameters. All
values below the limit of quantification were considered as zero
for pharmacokinetic analysis.
Statistical Analyses
Descript statistics were computed and reported for primary
and secondary pharmacokinetic parameters for trazodone.
Analysis of variance was performed using PROC MIXED
(SAS R©, version 9.3, SAS Institute Inc., USA1) for ln-transformed
pharmacokinetic parameters AUC0−∞, AUC0−t and Cmax for
trazodone. The ANOVA model included sequence, period
and formulation as fixed effects and subject (sequence) as a
random effect. Using two one-sided tests for bioequivalence,
90% confidence intervals (CIs) for the ratio of geometric least
squares means between drug formulations were calculated for
ln-transformed pharmacokinetic parameters AUC0−∞, AUC0−t,
and Cmax for trazodone. Bioequivalence was concluded if the 90%
CIs were within the range 80–125%. For all other parameters,
descriptive statistics were presented. The power of the study to
detect 20% difference between the test and reference formulations
was computed and reported for trazodone.
1SAS/STATR User’s Guide. SAS Institute Inc., USA, Version 9.3.
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Results
A total of 58 subjects were enrolled and checked in for the
study. As per the protocol 56 subjects were randomized [mean
(standard deviation) 30.2 ± 6.1 years, BMI 22.1 ± 2.3 kg/m2]
in period-I of the study. Two subjects were withdrawn from the
study on medical grounds and two on the grounds of emesis
in Period-I. Five subjects were withdrawn from the study on
medical grounds in Period-II. In all, 47 subjects completed the
clinical phase of the study successfully.
The trazodone plasma concentration-time profiles are shown
in Figures 1, 2 and pharmacokinetic parameters are summarized
in Tables 1, 2.
Trazodone was rapidly absorbed, with a median tmaxof 2 h
(Table 1). The plasma concentration-time curves of trazodone
showed a parallel decline in distribution and elimination phases
(Figure 1). The gMean values of Cmax, AUC0−t and AUC0−∞ for
trazodone were comparable for test and reference formulations
with low inter-individual variation (CV ranged from 9.2 to
13.1%). Bioequivalence was demonstrated as the 90% CIs of the
ratios of point estimates (test/reference) for Cmax, AUC0−t and
AUC0−∞ were within the range of 80–125%.
Safety Results
In general, the clinical portion of the study was completed
with nine (09) significant adverse events which resulted into
FIGURE 1 | Mean Plasma concentration vs. Time curve for Trazodone (Test Product—T and Reference Product—R)—Linear plot.
FIGURE 2 | Mean Plasma concentration vs. Time curve for Trazodone (Test Product—T and Reference Product—R)—Semi logarithmic Plot.
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TABLE 1 | Descriptive statistics of formulation means for Trazodone.
Parameters (units) Mean ± SD (un-transformed data)
Test product-T Reference product-R
Tmax (h)* 2.0 (0.667–6.02) 2.25 (0.667–6.0)
Cmax (ng/mL) 1521.8 ± 364.5 1546.9 ± 315.4
AUC0−t (ng.h/mL) 18864.6 ± 5374.1 18982.8 ± 5217.2
AUC0−∞ (ng.h /mL) 19959.8 ± 5442.8 20358.9 ± 5869.1
t½ (h) 12.9 ± 3.9 13.1 ± 3.5
*Tmax is represented as median (min-max) value.
TABLE 2 | Relative bioavailability results for Trazodone.
Parameters Geometric least squares means 90% confidence
interval
Test Reference Ratio
product-T product-R (T/R)%
lnCmax 1480.9 1520.2 97.4 93.01–102.04
lnAUC0−t 18193.1 18209.8 99.9 96.71–103.22
lnAUC0−∞ 19346.3 19393.4 99.8 96.10–103.55
withdrawal of the subjects from the study with the reasons
Giddiness and vomiting; drowsiness; upper respiratory tract
infection; chest pain; fever and headache; toothache and fever.
The investigational products were well tolerated by healthy
subjects, as a single dose administration. Twelve (12) adverse
events (AEs) were reported by ten (10) subjects during the
conduct of the study. Eleven (11) AEs were mild in nature and
one (01) AE was moderate in nature. The subjects were treated
accordingly and were followed up until resolution of their AEs.
The causality assessment was judged as possible for four (04) AEs,
as unlikely for three (03) AEs and as unrelated for two (02) AEs.
There were no deaths or serious adverse event during the
conduct of the study. There were no clinically significant findings
in the vital signs assessment or the laboratory tests in any of the
subjects.
Discussion
The ratio of geometric least squares means of Test product
and Reference Product for ln-transformed pharmacokinetic
parameter, Cmax was 97.4%. The 90% CIs for the ratio of
geometric least squares means was found to be 93.01–102.04%.
The ratio of geometric least squares means of Test product
and Reference Product for ln-transformed pharmacokinetic
parameter, AUC0−t was 99.9%. The 90% CI for the ratio of
geometric least squares means was found to be 96.71–103.22%.
The ratio of geometric least squares means of Test product
and Reference Product for ln-transformed pharmacokinetic
parameter, AUC0−t was 99.8%. The 90% CI for the ratio of
geometric least squares means was found to be 96.10–103.55%.
These intervals were within the acceptance limits of 80.00–
125.00%, required for the conclusion of bioequivalence as per
criteria set in the protocol.
Upon conclusion of the clinical portion of the study, the
results from all subjects, who completed post-study procedures
including laboratory tests and vital signs measurements,
confirmed the absence of significant changes in the subject’s state
of health.
In summary, Test Product when compared with the Reference
product meets the bioequivalence criteria with respect to the rate
and extent of absorption of Trazodone under fed conditions as
per criteria set in the protocol.
For the test formulation, the trazodone gMean Cmax
was 1480.9 ng/mL (vs. 1520.2 ng/mL for reference) which is
comparable to the published data 1470 ng/mL (Nilsen and Dale,
1992) where as in another study it was 1188 ng/mL after 300mg
extended release tablet (Jessica and Alan Caspi, 2011). In this
study AUC0−t was 18193.0 ng·h/mL (vs. 18209.8 ng·h/mL) and
AUC0−∞ was 19346.3 ng·h/mL (vs. 19393.4 ng·h/mL).
In another study the same drug was tested under fasting
conditions. For the test formulation, the trazodone gMean Cmax
was 2172.2 ng/mL (vs. 2031.2 ng/mL for reference), AUC0−t
was 16631.6 ng·h/mL (vs. 16342.9 ng·h/mL) and AUC0−∞ was
17460.6 ng·h/mL (vs. 17270.1 ng·h/mL) (Kale and Agrawal,
2015).
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